How a Federal Policy for Pharmacoequity Keeps Falling Short
Expansions of the 340B Program Have Enriched Some Organizations While Failing to Improve the Safety Net
Search Results
In The Media ABC
Eating Disorder Hospitalizations Doubled During COVID-19 Pandemic, New Data Shows
Work Cited
The Economic Burden of Parkinson’s Disease: Chart of the Day
Medicare Costs Rise with Advanced Disease
In The Media JAMA Network Open
The Changing Characteristics Of Technologies Covered By Medicare’s New Technology Add-On Payment Program
Authors
Twelve Penn Researchers Selected for 2020 LDI Pilot Research Grants
Early Stage HSR Projects Target Challenges in Health and Health Care Delivery
Managing The Coming Tsunami of Genomic and Cellular Therapy Cost and Access Issues
Penn LDI 'Cost of a Cure' Conference Convenes Top Experts Including FDA Commissioner
Balancing Affordability And Access: Lessons From New Cholesterol-Lowering Drugs
A Health Affairs blog
Prior Authorization Requirements for Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors Across US Private and Public Payers
Administrative requirements may limit access to treatment
Photo Page: Closing the LDI 50th Anniversary Symposium
Last Day Highlights Panels of Top Health Care Authorities Looking to The Future